NIKKEI 225
26,603.37 -201.23 (-0.75%) HANG SENG
21,996.89 0.00 (0.00%) CRUDE OIL
109.83 +0.05 (+0.05%) GOLD FUTURES
1,820.60 +3.10 (+0.17%) DOW
31,029.31 +82.32 (+0.27%) BTC-GBP
16,504.21 -346.65 (-2.06%)
Siemens Healthineers AG (SHL.DE)
| Previous close | 47.72 |
| Open | 47.18 |
| Bid | 47.52 x 0 |
| Ask | 47.55 x 0 |
| Day's range | 46.90 - 47.88 |
| 52-week range | 43.49 - 67.66 |
| Volume | |
| Avg. volume | 624,667 |
| Market cap | 53.17B |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | 28.02 |
| EPS (TTM) | 1.69 |
| Earnings date | 28 Jul 2022 - 01 Aug 2022 |
| Forward dividend & yield | 0.85 (1.78%) |
| Ex-dividend date | 16 Feb 2022 |
| 1y target est | 65.65 |
- Business Wire
Siemens Healthineers and The Ohio State University Wexner Medical Center Announce Strategic Partnership Focused on Personalized Medicine and Increased Access to High Quality Healthcare
MALVERN, Pa., June 28, 2022--Siemens Healthineers and The Ohio State University Wexner Medical Center announced a new alliance, aimed at advancing personalized medicine and improving access to high quality, cost-effective healthcare. Through the five-year strategic partnership, Siemens Healthineers and Varian, a Siemens Healthineers company, will provide comprehensive technology and services that will build on previous successful collaborative projects. The university and medical center will con
- EQS Group
Siemens Healthineers AG: Publication of a capital market information
DGAP-News: Siemens Healthineers AG / Key word(s): Share Buyback/Share BuybackSiemens Healthineers AG: Publication of a capital market information 27.06.2022 / 21:56 The issuer is solely responsible for the content of this announcement.Disclosure pursuant to Art. 5 para. 1 lit. a) of the Regulation (EU) No. 596/2014 (MAR) in conjunction with Art. 2 para. 1 of the Delegated Regulation (EU) No. 2016/1052The share buyback resolved on 24 June 2022 by the Managing Board of Siemens Healthineers AG (her
- Business Wire
Millions of Siemens Healthineers CLINITEST Rapid COVID-19 Antigen Self-Test Now Available in the U.S.
TARRYTOWN, N.Y., February 03, 2022--Siemens Healthineers announced today the CLINITEST® Rapid COVID-19 Antigen Self-Test1,2 is now available in the U.S. to self-test for the SARS-CoV-2 virus. The CLINITEST Rapid COVID-19 Antigen Self-Test uses a simple nasal swab to provide accurate COVID-19 test results (including for both the Omicron and Delta variants) in 15 minutes and comes in a five-test-per-box configuration—convenient for families, group, and/or serial testing needs. The test is approved
